Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced that stockholders approved all five proposals at its Special Meeting held April 20, 2026. The proposals are described in the definitive proxy statement on Schedule 14A filed March 24, 2026. Stockholders can obtain the proxy and related SEC filings for free at the SEC website or the company website.
Positive
- None.
Negative
- None.
News Market Reaction – JAGX
In the Apr 21 session, JAGX declined 0.81%, reflecting a mild negative market reaction. Argus tracked a peak move of +11.3% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | AI development update | Positive | +5.7% | Plan to use AI platforms to support crofelemer IF development and commercialization. |
| Apr 09 | Webcast reminder | Neutral | -2.6% | Announcement of investor webcast to discuss Q4 2025 financials and updates. |
| Apr 08 | CID trial progress | Positive | -2.6% | Completion of Canalevia-CA1 effectiveness study and extended conditional approval. |
| Apr 07 | 2025 financial results | Negative | -0.1% | Reported higher operating and net losses plus ongoing Nasdaq delisting risk. |
| Apr 02 | Conference sponsorship | Positive | -1.5% | Support for pediatric GI study with crofelemer showing parenteral support reductions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Jaguar news often involved strategic or clinical positives, yet price reactions have been mixed, with several positive developments followed by negative or flat moves, suggesting occasional divergence between news tone and near-term trading.
Over the last month, Jaguar issued multiple updates spanning financials, licensing, clinical progress, and AI-enabled development. Items like the AI initiative and intestinal failure data carried a positive tone, while 2025 results highlighted larger $53.6M net losses and Nasdaq listing pressure. Regulatory filings detailed licensing cash infusions and capital-structure stress. Against this backdrop, approval of all April 20, 2026 Special Meeting proposals follows an already active period of financial and strategic repositioning.
Key Terms
schedule 14a regulatory
proxy statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 20, 2026 (the "Special Meeting").
Five proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on March 24, 2026. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire